AMSACRINE GLUCONATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H19N3O3S.C6H12O7
Molecular Weight	589.614
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.COC1=C(NC2=C3C=CC=CC3=NC4=C2C=CC=C4)C=CC(NS(C)(=O)=O)=C1

InChI

InChIKey=XXNAQBNJPZNRSZ-IFWQJVLJSA-N

InChI=1S/C21H19N3O3S.C6H12O7/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21;7-1-2(8)3(9)4(10)5(11)6(12)13/h3-13,24H,1-2H3,(H,22,23);2-5,7-11H,1H2,(H,12,13)/t;2-,3-,4+,5-/m.1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3884748 | https://www.ncbi.nlm.nih.gov/pubmed/2752503

The gluconate formulation of amsacrine (AMSA) has better water solubility then DMA formulation. It was thus developed and investigated to determine if it would be less cardiotoxic than the widely used N,N-dimethylacetamide (DMA) formulation. Amsacrine gluconate is the anticancer agent, which was tested against refractory leukemia. Moreover, their cytotoxic activity was demonstrated in the in vitro studies on 48 specimens of 9 histologically different types of human malignancy. The use of the gluconate formulation of AMSA, which contains no dimethylacetamide, has been associated with three cases of cardiomyopathy. Also, paresthesia was found in one patient among 26 treated with AMSA gluconate. This preparation has no apparent advantage when compared with amsacrine lactate.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2602146	Binding Agent 1064
DNA topoisomerase II alpha 37 Target ID: CHEMBL1806 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10691026	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Acute non-lymphocytic leukemia 10 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948 https://www.ncbi.nlm.nih.gov/pubmed/3884748	Primary	Phase II 1132	Unknown Approved Use Unknown
Acute lymphocytic leukemia 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948 https://www.ncbi.nlm.nih.gov/pubmed/3884748	Primary	Phase II 1132	Unknown Approved Use Unknown
Chronic myeloid leukemia in blast crisis 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6580948 https://www.ncbi.nlm.nih.gov/pubmed/3884748	Primary	Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Chemieliva Pharmaceutical Co., Ltd	PBCM1421215
Smolecule	S518821	http://www.smolecule.com/products/s518821
THE BioTek	bt-259867	https://www.thebiotek.com/product/inhibitors/bt-259867

PubMed

Title	Date	PubMed
Phase II study of amsacrine gluconate in refractory leukemia.	1983 Dec	6580948

Patents

Sample Use Guides

In Vivo Use Guide

120 mg/m2 daily for 5 days

Route of Administration: Intravenous

In Vitro Use Guide

A total of 128 human tumors were placed in culture and tested against amsacrine. At 10 ug/ml amsacrine gluconate showed cytotoxic activity against breast, colon, and lung cancer as well as melanoma with an overall activity of 37%.

Name

Type

Language

AMSACRINE GLUCONATE

Common Name

English

METHANESULFONAMIDE, N-(4-(9-ACRIDINYLAMINO)-3-METHOXYPHENYL)-, MONO-D-GLUCONATE

Common Name

English

NSC-334213

Code

English

D-GLUCONIC ACID, COMPD. WITH N-(4-(9-ACRIDINYLAMINO)-3-METHOXYPHENYL)METHANESULFONAMIDE (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

22824017